AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
omaveloxolone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids not used as glucocorticosteroids | 5712 | 1474034-05-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The precise mechanism by which omaveloxolone exerts its therapeutic effect in patients with Friedreich’s ataxia is unknown. Omaveloxolone have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.304 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.687 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 51.404 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 20.654 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.400 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.360 | % | High | 1 |
| herg | hERG pIC50 | 5.035 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 15.885 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 88.512 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.640 | % | High | 1 |
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,MAP3K7,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PLK1,PRKDC,STK33,SYK,TEK | 31 | |||
| kinase-selectivity-class | GRK2,PDK1 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.321 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 17.298 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.440 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 8.570 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | Moderate | 0.71 | |
| pppb | Pig plasma protein binding (% unbound) | 0.690 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 31.915 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 6 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.490 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 8.995 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 28, 2023 | FDA | REATA PHARMACEUTICALS INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic cytolysis | 63.71 | 51.26 | 16 | 214 | 55037 | 110534032 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07XX25 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
| FDA MoA | N0000185506 | Cytochrome P450 3A4 Inducers |
| FDA MoA | N0000187063 | Cytochrome P450 2C8 Inducers |
| CHEBI has role | CHEBI:22586 | antioxidant |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:77307 | cardioprotective agent |
Related Drugs by ATC class:
N07XX Other nervous system drugs 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Friedreich’s ataxia | indication | 10394003 | DOID:12705 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 50MG | SKYCLARYS | BIOGEN US | N216718 | Feb. 28, 2023 | RX | CAPSULE | ORAL | 11091430 | April 20, 2029 | TREATMENT OF FRIEDREICHS ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER |
| 50MG | SKYCLARYS | BIOGEN US | N216718 | Feb. 28, 2023 | RX | CAPSULE | ORAL | 11919838 | April 20, 2029 | METHOD OF TREATING FRIEDRICHS ATAXIA BY ACTIVATING THE NRF2 PATHWAY |
| 50MG | SKYCLARYS | BIOGEN US | N216718 | Feb. 28, 2023 | RX | CAPSULE | ORAL | 11919838 | April 20, 2029 | METHOD OF TREATING FRIEDRICHS ATAXIA BY ACTIVATING THE NRF2 PATHWAY WHICH REDUCES OXIDATIVE STRESS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 50MG | SKYCLARYS | BIOGEN US | N216718 | Feb. 28, 2023 | RX | CAPSULE | ORAL | Dec. 20, 2027 | INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION |
| 50MG | SKYCLARYS | BIOGEN US | N216718 | Feb. 28, 2023 | RX | CAPSULE | ORAL | Feb. 28, 2028 | NEW CHEMICAL ENTITY |
| 50MG | SKYCLARYS | BIOGEN US | N216718 | Feb. 28, 2023 | RX | CAPSULE | ORAL | Feb. 28, 2030 | TREATMENT OF FRIEDREICHS ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Nuclear factor erythroid 2-related factor 2 | Transcription factor | ACTIVATOR | IC50 | 9.40 | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEBI:229661 | CHEBI |
| CHEMBL4303525 | ChEMBL_ID |
| C000589490 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7573 | IUPHAR_LIGAND_ID |
| DB12513 | DRUGBANK_ID |
| 4042120 | VANDF |
| C4519135 | UMLSCUI |
| 10135 | INN_ID |
| 71811910 | PUBCHEM_CID |
| 365409 | MMSL |
| 41269 | MMSL |
| d10017 | MMSL |
| 019329 | NDDF |
| D10964 | KEGG_DRUG |
| G69Z98951Q | UNII |
| 2631931 | RXNORM |
| G69Z98951Q | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| SKYCLARYS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64406-250 | CAPSULE | 50 mg | ORAL | NDA | 30 sections |
| SKYCLARYS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73179-250 | CAPSULE | 50 mg | ORAL | NDA | 29 sections |